The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2020 | European CAR-T climate: branching out
Alvaro Urbano, MD, BMT Unit, Barcelona, Spain, explores the current climate in European CAR-T scientific groups, including the preparation of their own genetic constructs and discusses the use of CAR-T technology outside of B-cell malignancies. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
